Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Divi's Lab

₹4522.2 16.3 | 0.4%

Market Cap ₹120049 Cr.

Stock P/E 74.9

P/B 8.8

Current Price ₹4522.2

Book Value ₹ 511.2

Face Value 2

52W High ₹4625

Dividend Yield 0.66%

52W Low ₹ 3300

Divi's Lab Research see more...

Overview Inc. Year: 1990Industry: Pharmaceuticals & Drugs

Divi's Laboratories Ltd manufactures Active Pharma Ingredients (APIs) and intermediates. The organization in a matter of short time multiplied their breadth of operations to offer whole turnkey solutions to the domestic Indian pharmaceutical enterprise.They are actively concerned in growing trade, patent non-infringing approaches for APIs, for the inventors to control late life cycle and leading customary drug producers.The company's product variety includes Bupropion Hbr,Bupropion HCL,Capecitabine,Carbidopa,Desloratadine,Dexlansoprazole /(R)-Lansoprazole, Irbesartan, Levodopa, Niacin, Sibutramine HCL, Valacyclovir HCL, Valsartan, Venlafaxine HCL, VerapamiL HCL, Vigabatrin, Zolpidem Tartrate ,and so forth.

Read More..

Divi's Lab Share Price

New

| |

Volume
Price

Quarterly Price

Show Value Show %

Divi's Lab Quarterly Results

#(Fig in Cr.) Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 2493 2518 2255 1855 1708 1951 1778 1909 1855 2303
Other Income 17 52 88 80 113 66 81 86 95 79
Total Income 2510 2571 2343 1935 1821 2017 1859 1995 1950 2382
Total Expenditure 1396 1414 1407 1234 1299 1464 1274 1430 1366 1572
Operating Profit 1114 1157 936 701 522 553 585 565 584 810
Interest 0 0 0 0 0 0 0 1 0 2
Depreciation 80 81 84 86 87 87 93 95 95 95
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 1034 1076 852 615 435 466 492 469 489 713
Provision for Tax 131 181 150 122 129 145 136 121 131 175
Profit After Tax 902 895 702 493 306 321 356 348 358 538
Adjustments 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 902 895 702 493 306 321 356 348 358 538
Adjusted Earnings Per Share 34 33.7 26.4 18.6 11.5 12.1 13.4 13.1 13.5 20.3

Divi's Lab Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 2145 2532 3115 3776 4064 3891 4946 5394 6969 8960 7768 7845
Other Income 45 71 45 97 75 113 156 190 63 116 345 341
Total Income 2190 2603 3160 3874 4139 4005 5102 5584 7032 9076 8112 8186
Total Expenditure 1329 1517 1949 2358 2617 2629 3073 3571 4108 5079 5398 5642
Operating Profit 861 1086 1211 1516 1522 1376 2029 2013 2924 3997 2714 2544
Interest 3 3 3 5 3 2 5 7 2 2 2 3
Depreciation 77 92 136 118 123 142 169 186 256 312 343 378
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 781 991 1072 1393 1395 1231 1855 1819 2666 3684 2369 2163
Provision for Tax 179 218 221 267 335 354 502 443 682 723 545 563
Profit After Tax 602 773 852 1126 1060 877 1353 1377 1984 2960 1823 1600
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 602 773 852 1126 1060 877 1353 1377 1984 2960 1823 1600
Adjusted Earnings Per Share 22.7 29.1 32.1 42.4 39.9 33 51 51.9 74.8 111.5 68.7 60.3

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -13% 13% 15% 14%
Operating Profit CAGR -32% 10% 15% 12%
PAT CAGR -38% 10% 16% 12%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 29% 2% 24% 21%
ROE Average 15% 22% 21% 23%
ROCE Average 19% 29% 28% 30%

Divi's Lab Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 2501 2963 3495 4293 5357 5925 6957 7310 9295 11728 12767
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 2 2 1 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 468 648 841 85 1412 1769 991 295 364 437 556
Total Current Liabilities 554 627 776 520 659 653 847 1821 1728 2454 1533
Total Liabilities 3525 4241 5112 4898 7429 8347 8795 9425 11387 14619 14857
Fixed Assets 909 1222 1309 1439 1559 1996 2088 2782 3704 4325 4723
Other Non-Current Assets 752 763 1031 432 1859 1816 2057 1070 892 684 390
Total Current Assets 1864 2256 2772 3027 4011 4535 4650 5574 6791 9610 9744
Total Assets 3525 4241 5112 4898 7429 8347 8795 9425 11387 14619 14857

Divi's Lab Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 17 12 15 18 -17 -4 -21 2 43 2030 1215
Cash Flow from Operating Activities 480 557 826 1038 1150 776 954 1216 1947 1912 2460
Cash Flow from Investing Activities -255 -305 -521 -406 -1140 -478 -685 -83 75 -2195 -2708
Cash Flow from Financing Activities -231 -248 -303 -631 2 -314 -246 -1091 -35 -532 -797
Net Cash Inflow / Outflow -5 3 3 0 13 -17 23 41 1987 -816 -1045
Closing Cash & Cash Equivalent 12 15 18 18 -4 -21 2 43 2030 1215 170

Divi's Lab Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 22.68 29.13 32.08 42.41 39.95 33.04 50.96 51.86 74.75 111.53 68.69
CEPS(Rs) 25.58 32.6 37.2 46.86 44.59 38.41 57.32 58.87 84.38 123.26 81.62
DPS(Rs) 15 20 20 10 10 10 16 16 20 30 30
Book NAV/Share(Rs) 94.2 111.63 131.67 161.73 201.82 223.2 262.09 275.38 350.15 441.82 480.96
Core EBITDA Margin(%) 37.77 39.81 37.12 37.28 35.24 32.27 37.6 33.41 40.92 43.18 30.3
EBIT Margin(%) 36.28 38.97 34.21 36.73 34.06 31.53 37.33 33.48 38.16 41 30.32
Pre Tax Margin(%) 36.17 38.85 34.12 36.61 33.98 31.47 37.24 33.35 38.13 40.98 30.29
PAT Margin (%) 27.87 30.32 27.1 29.59 25.82 22.41 27.15 25.23 28.38 32.94 23.32
Cash Profit Margin (%) 31.43 33.93 31.43 32.69 28.83 26.06 30.54 28.64 32.04 36.4 27.71
ROA(%) 19.17 19.92 18.21 22.49 17.21 11.12 15.78 15.11 19.07 22.77 12.37
ROE(%) 25.99 28.31 26.37 28.91 21.98 15.55 21 19.3 23.9 28.16 14.89
ROCE(%) 33.21 36.04 33.06 35.57 28.75 21.68 28.5 25.36 32.07 35.06 19.36
Receivable days 85.08 88.42 85.12 77.83 79.19 89.33 79.78 86.18 80.66 83.26 98.41
Inventory Days 127.96 126.52 121.69 113.7 112.34 124.56 114.41 121.62 104.66 100.99 136.05
Payable days 73.12 62.32 56.95 55.71 80.72 101.95 90.34 93.73 106.32 95.88 93.12
PER(x) 21.69 23.5 27.9 23.23 15.62 32.98 33.42 38.33 48.56 39.49 41.14
Price/Book(x) 5.22 6.13 6.8 6.09 3.09 4.88 6.5 7.22 10.37 9.97 5.88
Dividend Yield(%) 1.52 1.46 1.12 1.02 1.6 0.92 0.94 0.81 0.55 0.68 1.06
EV/Net Sales(x) 6.08 7.17 7.62 6.92 4.07 7.42 9.14 9.76 13.52 12.73 9.11
EV/Core EBITDA(x) 15.16 16.71 19.59 17.23 10.86 20.98 22.28 26.17 32.22 28.54 26.09
Net Sales Growth(%) 15.07 18.06 23.02 21.23 7.63 -4.25 27.1 9.06 29.2 28.56 -13.31
EBIT Growth(%) 14.39 26.8 8.16 30.01 0.08 -11.8 50.75 -1.78 46.07 38.13 -35.68
PAT Growth(%) 12.89 28.46 10.11 32.21 -5.81 -17.3 54.24 1.76 44.15 49.19 -38.41
EPS Growth(%) 12.89 28.46 10.11 32.21 -5.8 -17.3 54.24 1.76 44.15 49.19 -38.41
Debt/Equity(x) 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0 0 0 0
Current Ratio(x) 3.36 3.6 3.57 5.83 6.08 6.94 5.49 3.06 3.93 3.92 6.36
Quick Ratio(x) 1.85 2.11 2.08 3.5 4.08 4.87 3.4 2.04 2.69 2.76 4.4
Interest Cover(x) 302.96 336.24 373.59 294.75 416.28 520.55 397.38 255.83 1270.54 1842.75 1209.48
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Divi's Lab Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 51.95 51.94 51.94 51.94 51.94 51.94 51.93 51.93 51.92 51.92
FII 19.3 18.45 16.52 15.4 15.14 14.67 14.7 14.6 14.86 14.68
DII 17.73 18.32 19.98 20.78 20.67 21.08 21.23 21.75 21.88 22.21
Public 11.02 11.28 11.56 11.88 12.24 12.31 12.14 11.73 11.34 11.19
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 22%
  • Debtor days have improved from 95.88 to 93.12days.
  • Company is almost debt free.

Cons

  • Stock is trading at 8.8 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Divi's Lab News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....